- A high proportion of thyroid nodules that undergo fine-needle aspiration are classified as cytologically indeterminate
- Molecular testing offers a unique approach to improve risk stratification. This allows clinicians to assess indeterminate lesions and also prevents unnecessary surgical procedures
- Currently, 4 tests are commercially available, with ThyraMIR®/ThyGeNEXT® being two of the cheapest options
Outcomes of Molecular Testing in Cytologically Indeterminate Thyroid Nodules
AACE 2019, Edinburg, TX
